{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:02:55Z","timestamp":1791471775582,"version":"4.3.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s13555-026-01833-8","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T16:09:04Z","timestamp":1782576544000},"page":"4217-4225","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Abrocitinib Achieves Early and Complete\/Near-Complete Skin Clearance Plus Itch-Free State in Atopic Dermatitis: Phase 3 Pooled Post Hoc Analysis"],"prefix":"10.1007","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct04345367","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03720470","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03422822","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Stephen","family":"Weidinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Reich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naiem","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Chih-ho","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher G.","family":"Bunick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinaki","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erman","family":"G\u00fcler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3006-1675","authenticated-orcid":false,"given":"Justine","family":"Alderfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"issue":"10247","key":"1833_CR1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","volume":"396","author":"SM Langan","year":"2020","unstructured":"Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345\u201360.","journal-title":"Lancet"},{"issue":"9","key":"1833_CR2","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/jdv.18345","volume":"36","author":"A Wollenberg","year":"2022","unstructured":"Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I\u2014systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409\u201331.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"1833_CR3","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.jaad.2023.08.102","volume":"90","author":"DMR Davis","year":"2024","unstructured":"Davis DMR, Drucker AM, Alikhan A, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. J Am Acad Dermatol. 2024;90(2):e43\u201356.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"1833_CR4","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1111\/jdv.20229","volume":"38","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Gooderham M, Katoh N, et al. Combining treat-to-target principles and shared decision-making: international expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis. J Eur Acad Dermatol Venereol. 2024;38(11):2139\u201348.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"1833_CR5","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/jdv.18170","volume":"36","author":"S Stander","year":"2022","unstructured":"Stander S, Bhatia N, Gooderham MJ, et al. High threshold efficacy responses in moderate-to-severe atopic dermatitis are associated with additional quality of life benefits: pooled analyses of abrocitinib monotherapy studies in adults and adolescents. J Eur Acad Dermatol Venereol. 2022;36(8):1308\u201317.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10348","key":"1833_CR6","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0140-6736(22)01199-0","volume":"400","author":"K Reich","year":"2022","unstructured":"Reich K, Thyssen JP, Blauvelt A, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Lancet. 2022;400(10348):273\u201382.","journal-title":"Lancet"},{"issue":"12","key":"1833_CR7","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","volume":"384","author":"T Bieber","year":"2021","unstructured":"Bieber T, Simpson EL, Silverberg JI, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021;384(12):1101\u201312.","journal-title":"N Engl J Med"},{"issue":"10","key":"1833_CR8","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1111\/jdv.19280","volume":"37","author":"K Reich","year":"2023","unstructured":"Reich K, Silverberg JI, Papp KA, et al. Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study. J Eur Acad Dermatol Venereol. 2023;37(10):2056\u201366.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1833_CR9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/bjd\/ljae404","volume":"192","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Bunick CG, Hong HC, et al. Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb\/IV study (Level Up). Br J Dermatol. 2024;192(1):36\u201345.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1833_CR10","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40257-024-00869-w","volume":"25","author":"EL Simpson","year":"2024","unstructured":"Simpson EL, Silverberg JI, Nosbaum A, et al. Integrated safety update of abrocitinib in 3802 patients with moderate-to-severe atopic dermatitis: data from more than 5200 patient-years with up to 4 years of exposure. Am J Clin Dermatol. 2024;25(4):639\u201354.","journal-title":"Am J Clin Dermatol"},{"key":"1833_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.70439","author":"MJ Gooderham","year":"2026","unstructured":"Gooderham MJ, Silverberg JI, De Bruin-Weller M, et al. Long-term efficacy of abrocitinib in patients with moderate-to-severe atopic dermatitis to 2\u2009years. J Eur Acad Dermatol Venereol. 2026. https:\/\/doi.org\/10.1111\/jdv.70439.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1833_CR12","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1007\/s13555-026-01679-0","volume":"16","author":"HE Gwag","year":"2026","unstructured":"Gwag HE, Park M, Park SY, et al. Real-world effectiveness and safety of abrocitinib in patients with atopic dermatitis: a 16-week single-center retrospective cohort study compared with upadacitinib and baricitinib. Dermatol Ther (Heidelb). 2026;16(3):1813\u201330.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"1833_CR13","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1111\/all.15969","volume":"79","author":"E Guttman-Yassky","year":"2024","unstructured":"Guttman-Yassky E, Facheris P, Gomez-Arias PJ, et al. Effect of abrocitinib on skin biomarkers in patients with moderate-to-severe atopic dermatitis. Allergy. 2024;79(5):1258\u201370.","journal-title":"Allergy"},{"key":"1833_CR14","doi-asserted-by":"crossref","unstructured":"Armstrong AW, Alexis AF, Blauvelt A, et al. Predicting Abrocitinib Efficacy at Week 12 Based on Clinical Response at Week 4: A Post Hoc Analysis of Four Randomized Studies in Moderate-to-Severe Atopic Dermatitis. Dermatol Ther (Heidelb). 2024;14(7):1849\u20131861.","DOI":"10.1007\/s13555-024-01183-3"},{"key":"1833_CR15","unstructured":"European Medicines Agency. Cibinqo (abrocitinib). Summary of product characteristics. 2024. Pfizer Europe MA EEIG. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cibinqo-epar-product-information_en.pdf. Accessed 22 June 2026."}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01833-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01833-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01833-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T16:30:13Z","timestamp":1787243413000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01833-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1833"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01833-8","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"25 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Stephen Weidinger is a speaker, advisory board member, and\/or investigator for AbbVie, Almirall, Boehringer Ingelheim, Eli Lilly, Galderma, GSK, LEO Pharma, Pfizer, Regeneron, and Sanofi; he has also received institutional research grants from LEO Pharma, Pfizer, and Sanofi. Kristian Reich has served as advisor and\/or paid speaker for and\/or participated in clinical trials sponsored by AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Forward Pharma, Gilead, Galderma, Janssen-Cilag, Kyowa Kirin, LEO Pharma, Lilly, Medac, Novartis, Ocean Pharma, Pfizer, and Sanofi, UCB. Naiem Issa has received funding from the following entities either as a speaker, consultant, advisor, or investigator: Abbvie, Almirall, Bristol Myers Squibb, Castle Biosciences, Dermavant Sciences, DermTech, Galderma, Incyte, Journey, LEO Pharma, Lilly, National Eczema Association, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, SUN Pharmaceuticals Industry, Topix, UCB, Verrica Pharmaceuticals. Kristian Reich is co-founder of Moonlake Immunotherapeutics. Naiem Issa has acted as a speaker, consultant, and\/or advisor for AbbVie, Almirall, Bristol Myers Squibb, Castle Biosciences, Dermavant Sciences, DermTech, Galderma, Incyte, Journey, LEO Pharma, Lilly, National Eczema Association, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, SUN Pharma, UCB, Verrica Pharmaceuticals, and WebMD. H. Chih-ho Hong is a researcher, consultant, and\/or advisor for Pfizer Inc., AbbVie, Amgen, Arcutis, ASLAN pharmaceutics, Bausch Health, Boehringer Ingelheim, Bristol Meyers Squibb, Celgene, Celltrion, Cutanea, Dermira, Dermavant, DS Biopharma, Eli Lilly, Evelo Biosciences, Galderma, GSK, Incyte, IQVIA, JAMP, Janssen, LEO Pharma, Medimmune, Merck, Mirimar, Novartis, Organanon, Regeneron, Sanofi-Genzyme, Sun Pharma, and UCB. Christopher G. Bunick has served as an investigator and\/or consultant for AbbVie, Almirall, Alumis, Amgen, Apogee, Arcutis, Botanix, Castle Biosciences, Connect BioPharma, Daiichi Sankyo, Dermavant, Eli Lilly, EPI Health\/Novan, Galderma, Incyte, LEO Pharma, Novartis, Ortho Dermatologics, Palvella, Pfizer, Regeneron, Sanofi, South Beach Symposium, Sun Pharma, Takeda, Timber, Teladoc, Triveni, and UCB. Pinaki Biswas, Gary Chan, Erman G\u00fcler, Melissa Watkins, and Justine Alderfer are employees and shareholders of Pfizer, Inc.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All study documents and procedures were approved by the appropriate institutional review boards\/ethics committees at each study site. The studies were conducted in compliance with the ethical principles from the Declaration of Helsinki and all International Council for Harmonisation Good Clinical Practice guidelines. All local regulatory requirements were followed. Informed consent was obtained from all individual participants included in the studies.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}